Reversal of late septic shock with supraphysiologic doses of hydrocortisone
- 1 April 1998
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 26 (4) , 645-650
- https://doi.org/10.1097/00003246-199804000-00010
Abstract
Preliminary studies have suggested that low doses of corticosteroids might rapidly improve hemodynamics in late septic shock treated with catecholamines. We examined the effect of hydrocortisone on shock reversal, hemodynamics, and survival in this particular setting. Prospective, randomized, double-blind, placebo-controlled study. Two intensive care units of a University hospital. Forty-one patients with septic shock requiring catecholamine for >48 hrs. Patients were randomly assigned either hydrocortisone (100 mg iv three times daily for 5 days) or matching placebo. Reversal of shock was defined by a stable systolic arterial pressure (>90 mm Hg) for >or=to24 hrs without catecholamine or fluid infusion. Of the 22 hydrocortisone-treated patients and 19 placebo-treated patients, 15 (68%) and 4 (21%) achieved 7-day shock reversal, respectively, a difference of 47% (95% confidence interval 17% to 77%; p=.007). Serial invasive hemodynamic measurements for 5 days did not show significant differences between both groups. At 28-day follow-up, reversal of shock was higher in the hydrocortisone group (p=.005). Crude 28-day mortality was 7 (32%) of 22 treated patients and 12 (63%) of 19 placebo patients, a difference of 31% (95% confidence interval 1% to 61%; p=.091). Shock reversal within 7 days after the onset of corticosteroid therapy was a very strong predictor of survival. There were no significant differences in outcome in responders and nonresponders to a short corticotropin test. The respective rates of gastrointestinal bleeding and secondary infections did not differ between both groups. Administration of modest doses of hydrocortisone in the setting of pressor-dependent septic shock for a mean of >96 hrs resulted in a significant improvement in hemodynamics and a beneficial effect on survival. These beneficial effects do not appear related to adrenocortical insufficiency. (Crit Care Med 1998;26:645-650)Keywords
This publication has 32 references indexed in Scilit:
- Incidence, Risk Factors, and Outcome of Severe Sepsis and Septic Shock in AdultsJAMA, 1995
- Corticosteroid treatment for sepsisCritical Care Medicine, 1995
- Steroid controversy in sepsis and septic shockCritical Care Medicine, 1995
- Selected Treatment Strategies for Septic Shock Based on Proposed Mechanisms of PathogenesisAnnals of Internal Medicine, 1994
- Cortisol response to corticotropin and survival in septic shockThe Lancet, 1991
- Sepsis, the Sepsis Syndrome, Multi-Organ Failure: A Plea for Comparable DefinitionsAnnals of Internal Medicine, 1991
- A Controlled Clinical Trial of High-Dose Methylprednisolone in the Treatment of Severe Sepsis and Septic ShockNew England Journal of Medicine, 1987
- The Effects of High-Dose Corticosteroids in Patients with Septic ShockNew England Journal of Medicine, 1984
- Steroids in the Treatment of Clinical Septic ShockAnnals of Surgery, 1976
- Medical Responsibility in OrtheticsJAMA, 1963